LLY - ELI LILLY & Co
Close
777.265
1.655 0.213%
Share volume: 46,506
Last Updated: Thu 02 Jan 2025 08:30:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.50%
PREVIOUS CLOSE
CHG
CHG%
$775.61
1.66
0.21%
Fundamental analysis
71%
Profitability
90%
Dept financing
25%
Liquidity
50%
Performance
70%
Performance
5 Days
-0.24%
1 Month
-3.48%
3 Months
-13.36%
6 Months
-14.86%
1 Year
30.33%
2 Year
111.02%
Key data
Stock price
$777.26
DAY RANGE
$771.87 - $786.62
52 WEEK RANGE
$618.76 - $972.53
52 WEEK CHANGE
$25.60
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news